Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00313586
Status:
COMPLETED
Last Update Posted:
2017-02-02
First Post:
2006-04-11
Brief Title:
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome |
| Adult Acute Myeloid Leukemia in Remission |
| Adult Acute Myeloid Leukemia With Inv16p131q22 CBFB-MYH11 |
| Adult Acute Myeloid Leukemia With t1616p131q22 CBFB-MYH11 |
| Adult Acute Myeloid Leukemia With t821q22q22 RUNX1-RUNX1T1 |
| Adult Acute Myeloid Leukemia With t911p22q23 MLLT3-MLL |
| Adult Acute Promyelocytic Leukemia With t1517q22q12 PML-RARA |
| Alkylating Agent-Related Acute Myeloid Leukemia |
| Chronic Myelomonocytic Leukemia |
| de Novo Myelodysplastic Syndrome |
| Previously Treated Myelodysplastic Syndrome |
| Recurrent Adult Acute Myeloid Leukemia |
| Secondary Acute Myeloid Leukemia |
| Secondary Myelodysplastic Syndrome |
| Untreated Adult Acute Myeloid Leukemia |
Keywords: